<DOC>
	<DOC>NCT01138488</DOC>
	<brief_summary>This trial was conducted in Europe. The aim of this study was to investigate the total exposure of NN5401 (insulin degludec/insulin aspart) in children, adolescents and adult subjects with type 1 diabetes.</brief_summary>
	<brief_title>A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months Body mass index for children: 15.020.0 kg/m^2 (both inclusive), for adolescents: 18.028.0 kg/m^2 (both inclusive) and for adults maximum 30.0 kg/m^2 Subject who has donated any blood or plasma in the past month, or more than 500 mL within 3 months prior to screening Not able or willing to refrain from smoking during the inpatient period Female of childbearing potential who is pregnant, breastfeeding or intends to become pregnant or is not using adequate contraceptive methods</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>